|
Mountain View, Calif., October 29, 2003 /PRNewswire/ SurroMed, Inc. today announced that it has been awarded a contract from the National Heart Lung and Blood Institute of the NIH. Pursuant to the contract SurroMed will apply its integrated biological marker discovery technologies to clinical samples of patients with in-stent restenosis. SurroMed will perform proteomic and metabolomic profiling, and NIH investigators will undertake gene expression analysis of the same samples.
“Biomarkers are urgently needed for the accurate stratification of patients at risk for restenosis,” said Gordon Ringold, Ph. D., SurroMed’s Chairman and CEO. “In-stent restenosis currently complicates 20-50% of intracoronary stent implantation procedures and results in significant patient morbidity. Availability of biomarkers to determine those patients at risk for restenosis would enable targeted and individualized prescription of anti-restenotic therapies, such as drug eluting stents.”
About SurroMed, Inc. - The Biomarker Company
SurroMed is pioneering biomarker enabled drug discovery and development. The company
focuses on discovering and applying biomarkers to improve the drug discovery and
development process and enable the precise diagnosis and personalized treatment of
disease. SurroMed's research process yields biological markers and information that
enable accelerated, cost-efficient discovery and development of new therapeutic products,
as well as development of diagnostic tests for early disease detection, disease staging,
patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|
